Other Information
−Removed: During the three months ended June 30, 2024, an affiliate of the Company, Samsara BioCapital, L.P.
−Removed: (Samsara), entered into a Rule 10b5-1 trading plan (the Samsara 10b5-1 Plan).
−Removed: The Samsara 10b5-1 Plan, entered into on May 3, 2024 , is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act and provides for the sale of up to 1,691,638 shares of the Company’s common stock from time to time between August 12, 2024 and April 29, 2026.
−Removed: The Samsara 10b5-1 Plan will expire on April 29, 2026 , or earlier if all shares under the plan are sold prior to that date.
−Removed: Srinivas Akkaraju , M.D., Ph.D., one of our directors , is Managing General Partner of Samara and has voting and investment power over the shares held by Samsara.
+Added: During the three months ended September 30, 2024, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated any contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any non-Rule 10b5-1 trading arrangement (as defined in the SEC’s rules).
Number Incorporated by Reference Filed Herewith
21 unchanged sentences
MINERALYS THERAPEUTICS, INC.
−Removed: August 13, 2024 By:
+Added: November 12, 2024 By:
/s/ Jon Congleton
2 unchanged sentences
(Principal Executive Officer)
−Removed: August 13, 2024 By:
+Added: November 12, 2024 By:
/s/ Adam Levy
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.